Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 4/20 | 0.53 |
| ▸ | APP | P05067 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.52 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18429639 | 0.85 | APP (0.70) | APPCYP3A4 | |
| SCHEMBL16846466 | 0.81 | APP (0.66) | MAOBAPPRAB9ASMN1; SMN2 | |
| SCHEMBL2307022 | 0.79 | P4HTM (0.58) | P4HTMLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL30879831 | 0.79 | P4HTM (0.58) | P4HTMLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL30362841 | 0.79 | MAOB (0.61) | P4HTMLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL2648020 | 0.79 | MAOB (0.61) | P4HTMLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL1103901 | 0.79 | P4HTM (0.58) | P4HTMLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL113439 | 0.79 | P4HTM (0.58) | P4HTMLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL228033 | 0.79 | P4HTM (0.58) | P4HTMLMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL940824 | 0.79 | P4HTM (0.58) | P4HTMLMNACYP1A2PTGS1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108541302-B | Urea-based Prostate Specific Membrane Antigen (PSMA) inhibitors for imaging and therapy | 五一一制药股份有限公司 | 2023-02-14 | — | — | CN | disclosed |
| EP-3397968-B1 | UREA-BASED PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS FOR IMAGING AND THERAPY | FIVE ELEVEN PHARMA INC (US) | 2021-09-29 | — | — | EP | disclosed |
| US-10688200-B2 | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy | FIVE ELEVEN PHARMA INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-10688200-B2 | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy | FIVE ELEVEN PHARMA INC. (US) | 2020-06-23 | — | — | US | disclosed |
| WO-2017116994-A1 | UREA-BASED PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS FOR IMAGING AND THERAPY | FIVE ELEVEN PHARMA INC. (US) | 2017-07-06 | — | — | WO | disclosed |
| US-20170189568-A1 | UREA-BASED PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS FOR IMAGING AND THERAPY | FIVE ELEVEN PHARMA INC. | 2017-07-06 | — | — | US | disclosed |
| US-20170189568-A1 | UREA-BASED PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS FOR IMAGING AND THERAPY | FIVE ELEVEN PHARMA INC. | 2017-07-06 | — | — | US | disclosed |
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189568-A1 | UREA-BASED PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS FOR IMAGING AND THERAPY | KLK3, FOLH1, UTS2R | P4HTM 1247/4885LMNA 4549/4885CYP1A2 4729/4885 |
| US-10688200-B2 | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy | KLK3, FOLH1, UTS2R | P4HTM 1247/4885LMNA 4549/4885CYP1A2 4729/4885 |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | P4HTM 1571/4885LMNA 2720/4885CYP1A2 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.